Alterome Therapeutics raises $132 million in a Series B financing led by Goldman Sachs Alternatives.
Alterome Therapeutics raises $132 million in a Series B financing led by Goldman Sachs Alternatives.
04/03/24, 10:11 AM
Location
Money raised
$132 million
Round Type
series b
Investors
Colt Ventures, Boxer Capital, Vida Ventures, Nextech Invest, Orbimed, Blue Owl Capital, Digitalis Ventures, Driehaus Capital Management, Invus, Canaan Partners, Goldman Sachs Alternatives
Alterome Therapeutics, Inc. announced the closing of a $132 million Series B financing. The proceeds will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic.
Company Info
Location
san diego, california, united states
Additional Info
Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!